Literature DB >> 23723299

HMGB1 in cancer: good, bad, or both?

Rui Kang1, Qiuhong Zhang, Herbert J Zeh, Michael T Lotze, Daolin Tang.   

Abstract

Forty years ago, high mobility group box 1 (HMGB1) was discovered in calf thymus and named according to its electrophoretic mobility in polyacrylamide gels. Now, we know that HMGB1 performs dual functions. Inside the cell, HMGB1 is a highly conserved chromosomal protein acting as a DNA chaperone. Outside of the cell, HMGB1 is a prototypical damage-associated molecular pattern, acting with cytokines, chemokines, and growth factors. During tumor development and in cancer therapy, HMGB1 has been reported to play paradoxical roles in promoting both cell survival and death by regulating multiple signaling pathways, including inflammation, immunity, genome stability, proliferation, metastasis, metabolism, apoptosis, and autophagy. Here, we review the current knowledge of both HMGB1's oncogenic and tumor-suppressive roles and the potential strategies that target HMGB1 for the prevention and treatment of cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23723299      PMCID: PMC3732559          DOI: 10.1158/1078-0432.CCR-13-0495

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  75 in total

Review 1.  Priming the nucleosome: a role for HMGB proteins?

Authors:  Andrew A Travers
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

2.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

3.  Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β.

Authors:  Nicolas Dupont; Shanya Jiang; Manohar Pilli; Wojciech Ornatowski; Dhruva Bhattacharya; Vojo Deretic
Journal:  EMBO J       Date:  2011-11-08       Impact factor: 11.598

4.  HMGB1 promotes drug resistance in osteosarcoma.

Authors:  Jun Huang; Jiangdong Ni; Ke Liu; Yan Yu; Min Xie; Rui Kang; Philip Vernon; Lizhi Cao; Daolin Tang
Journal:  Cancer Res       Date:  2011-11-18       Impact factor: 12.701

5.  Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.

Authors:  U M Ohndorf; M A Rould; Q He; C O Pabo; S J Lippard
Journal:  Nature       Date:  1999-06-17       Impact factor: 49.962

6.  Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Authors:  Mickaël Michaud; Isabelle Martins; Abdul Qader Sukkurwala; Sandy Adjemian; Yuting Ma; Patrizia Pellegatti; Shensi Shen; Oliver Kepp; Marie Scoazec; Grégoire Mignot; Santiago Rello-Varona; Maximilien Tailler; Laurie Menger; Erika Vacchelli; Lorenzo Galluzzi; François Ghiringhelli; Francesco di Virgilio; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2011-12-16       Impact factor: 47.728

7.  Yeast Nhp6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability.

Authors:  Sabrina Giavara; Effie Kosmidou; M Prakash Hande; Marco E Bianchi; Alan Morgan; Fabrizio d'Adda di Fagagna; Stephen P Jackson
Journal:  Curr Biol       Date:  2005-01-11       Impact factor: 10.834

8.  The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.

Authors:  Stefania Gardella; Cristina Andrei; Denise Ferrera; Lavinia V Lotti; Maria R Torrisi; Marco E Bianchi; Anna Rubartelli
Journal:  EMBO Rep       Date:  2002-09-13       Impact factor: 8.807

9.  The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.

Authors:  O Hori; J Brett; T Slattery; R Cao; J Zhang; J X Chen; M Nagashima; E R Lundh; S Vijay; D Nitecki
Journal:  J Biol Chem       Date:  1995-10-27       Impact factor: 5.157

10.  Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.

Authors:  Henri J Huttunen; Carole Fages; Juha Kuja-Panula; Anne J Ridley; Heikki Rauvala
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  207 in total

1.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

Review 2.  Post-translational modifications of high mobility group box 1 and cancer.

Authors:  Seidu A Richard; Yuanyuan Jiang; Lu Hong Xiang; Shanshan Zhou; Jia Wang; Zhaoliang Su; Huaxi Xu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

3.  miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy.

Authors:  Shibing Guo; Rui Bai; Wanlin Liu; Aiqing Zhao; Zhenqun Zhao; Yuxin Wang; Yong Wang; Wei Zhao; Wenxuan Wang
Journal:  Tumour Biol       Date:  2014-04-22

4.  Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells.

Authors:  Jing Zhang; Cang Liu; Ruiguang Hou
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

5.  Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress.

Authors:  Samer Tohme; Hamza O Yazdani; Ahmed B Al-Khafaji; Alexis P Chidi; Patricia Loughran; Kerri Mowen; Yanming Wang; Richard L Simmons; Hai Huang; Allan Tsung
Journal:  Cancer Res       Date:  2016-01-12       Impact factor: 12.701

6.  Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.

Authors:  Jayson Hardcastle; Lisa Mills; Courtney S Malo; Fang Jin; Cheyne Kurokawa; Hirosha Geekiyanage; Mark Schroeder; Jann Sarkaria; Aaron J Johnson; Evanthia Galanis
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

7.  High mobility group box 1 (HMGB1) phenotypic role revealed with stress.

Authors:  Daolin Tang; Rui Kang; Bennett Van Houten; Herbert J Zeh; Timothy R Billiar; Michael T Lotze
Journal:  Mol Med       Date:  2014-08-19       Impact factor: 6.354

8.  Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway.

Authors:  Meng Zhou; Zhifa Wen; Feng Cheng; Jie Ma; Weixia Li; Hongyan Ren; Yemeng Sheng; Huixia Dong; Liwei Lu; Hong-Ming Hu; Li-Xin Wang
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

9.  Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Li Jia; Andrew Clear; Feng-Ting Liu; Janet Matthews; Nadiha Uddin; Aine McCarthy; Elena Hoxha; Catherine Durance; Sameena Iqbal; John G Gribben
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

10.  Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis.

Authors:  Lucia Cottone; Annalisa Capobianco; Chiara Gualteroni; Antonella Monno; Isabella Raccagni; Silvia Valtorta; Tamara Canu; Tiziano Di Tomaso; Angelo Lombardo; Antonio Esposito; Rosa Maria Moresco; Alessandro Del Maschio; Luigi Naldini; Patrizia Rovere-Querini; Marco E Bianchi; Angelo A Manfredi
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.